Adaptive Biotechnologies projected at least 20% year-over-year MRD revenue growth for 2026, driven by increased adoption of its ClonoSeq minimal residual disease assay across oncology settings and growing clinical endorsement of MRD as an endpoint. The Seattle-based firm reported Q4 revenue up 54% year over year and outlined plans to scale EMR integrations, expand community penetration and raise average selling price via payor renegotiations. CEO Chad Robins and CFO Kyle Piskel highlighted expectations for 30% test volume growth and incremental milestone revenue. Adaptive also flagged a strategic push to grow MRD services supporting registrational trials across multiple hematologic malignancies, positioning the diagnostics business as a durable revenue engine as the company commercializes expanded clinical utility.